NASDAQ:ATRA
Atara Biotherapeutics Stock News
$0.690
-0.0098 (-1.40%)
At Close: Apr 26, 2024
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
10:41am, Thursday, 28'th Mar 2024
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago.
Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
07:24pm, Monday, 05'th Feb 2024
Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treati
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:01pm, Thursday, 04'th Jan 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
06:05pm, Wednesday, 29'th Nov 2023
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List
03:14pm, Wednesday, 22'nd Nov 2023
Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 1
11 Top Penny Stocks To Buy Now According To Insiders
01:32pm, Friday, 17'th Nov 2023
Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to
5 Penny Stocks To Buy Now According To Insiders
12:52pm, Wednesday, 15'th Nov 2023
Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity
02:13am, Monday, 13'th Nov 2023
Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring,
Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript
11:45am, Saturday, 04'th Nov 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - Presid
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
10:31am, Thursday, 21'st Sep 2023
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates
06:56pm, Tuesday, 08'th Aug 2023
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.31 per share a year ago.
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
04:01pm, Wednesday, 07'th Jun 2023
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
07:02pm, Monday, 08'th May 2023
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.87 per share a year ago.
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
12:08pm, Sunday, 16'th Apr 2023
In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Wednesday, 08'th Feb 2023
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto